4.6 Review

Drug repurposing for breast cancer therapy: Old weapon for new battle

期刊

SEMINARS IN CANCER BIOLOGY
卷 68, 期 -, 页码 8-20

出版社

ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
DOI: 10.1016/j.semcancer.2019.09.012

关键词

Breast cancer; Multitargeting; Non-cancer drug; OMICS; Serendipity

类别

资金

  1. Science and Engineering Research Board [ECR/2016/000034]
  2. University Grants Commission [30-112/2015 (BSR)]
  3. DBT New Delhi [DBT/2017/BHU/786]

向作者/读者索取更多资源

Drug repurposing is a novel approach for drug development that involves repositioning clinically approved non-cancer drugs with known targets to newer indications, resulting in faster, more effective, cheaper, and safer drugs with reduced known side effects. Several drugs have been successfully repositioned for breast cancer treatment, especially for the most aggressive triple negative breast cancer. Serendipity plays a key role in drug development, and challenges associated with drug repurposing are also discussed in the literature.
Despite tremendous resources being invested in prevention and treatment, breast cancer remains a leading cause of cancer deaths in women globally. The available treatment modalities are very costly and produces severe side effects. Drug repurposing that relate to new uses for old drugs has emerged as a novel approach for drug development. Repositioning of old, clinically approved, off patent non-cancer drugs with known targets, into newer indication is like using old weapons for new battle. The advances in genomics, proteomics and information computational biology has facilitated the process of drug repurposing. Repositioning approach not only fastens the process of drug development but also offers more effective, cheaper, safer drugs with lesser/known side effects. During the last decade, drugs such as alkylating agents, anthracyclins, antimetabolite, CDK4/6 inhibitor, aromatase inhibitor, mTOR inhibitor and mitotic inhibitors has been repositioned for breast cancer treatment. The repositioned drugs have been successfully used for the treatment of most aggressive triple negative breast cancer. The literature review suggest that serendipity plays a major role in the drug development. This article describes the comprehensive overview of the current scenario of drug repurposing for the breast cancer treatment. The strategies as well as several examples of repurposed drugs are provided. The challenges associated with drug repurposing are discussed.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据